and National Reference Center for Rabies National Reference Center and Collaborating Center for Diseases at the Animal Human Interface Instituto Zooprofilattico Sperimentale delle Venezie Legnaro

Italy

and National Reference Center for Rabies National Reference Center and Collaborating Center for Diseases at the Animal Human Interface Instituto Zooprofilattico Sperimentale delle Venezie Legnaro

Italy
SEARCH FILTERS
Time filter
Source Type

De Benedictis P.,and National Reference Center for Rabies National Reference Center and Collaborating Center for Diseases at the Animal Human Interface Instituto Zooprofilattico Sperimentale delle Venezie Legnaro | Minola A.,Humabs Biomedical SA Bellinzona Switzerland | Rota Nodari E.,and National Reference Center for Rabies National Reference Center and Collaborating Center for Diseases at the Animal Human Interface Instituto Zooprofilattico Sperimentale delle Venezie Legnaro | Aiello R.,and National Reference Center for Rabies National Reference Center and Collaborating Center for Diseases at the Animal Human Interface Instituto Zooprofilattico Sperimentale delle Venezie Legnaro | And 16 more authors.
EMBO Molecular Medicine | Year: 2016

Currently available rabies post-exposure prophylaxis (PEP) for use in humans includes equine or human rabies immunoglobulins (RIG). The replacement of RIG with an equally or more potent and safer product is strongly encouraged due to the high costs and limited availability of existing RIG. In this study, we identified two broadly neutralizing human monoclonal antibodies that represent a valid and affordable alternative to RIG in rabies PEP. Memory B cells from four selected vaccinated donors were immortalized and monoclonal antibodies were tested for neutralizing activity and epitope specificity. Two antibodies, identified as RVC20 and RVC58 (binding to antigenic site I and III, respectively), were selected for their potency and broad-spectrum reactivity. In vitro, RVC20 and RVC58 were able to neutralize all 35 rabies virus (RABV) and 25 non-RABV lyssaviruses. They showed higher potency and breath compared to antibodies under clinical development (namely CR57, CR4098, and RAB1) and commercially available human RIG. In vivo, the RVC20-RVC58 cocktail protected Syrian hamsters from a lethal RABV challenge and did not affect the endogenous hamster post-vaccination antibody response. © 2016 EMBO.

Loading and National Reference Center for Rabies National Reference Center and Collaborating Center for Diseases at the Animal Human Interface Instituto Zooprofilattico Sperimentale delle Venezie Legnaro collaborators
Loading and National Reference Center for Rabies National Reference Center and Collaborating Center for Diseases at the Animal Human Interface Instituto Zooprofilattico Sperimentale delle Venezie Legnaro collaborators